These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 15015601

  • 21. Soybean Bowman-Birk protease inhibitor (BBI): identification of the mechanisms of BBI suppressive effect on growth of two adenocarcinoma cell lines: AGS and HT29.
    Fereidunian A, Sadeghalvad M, Oscoie MO, Mostafaie A.
    Arch Med Res; 2014 Aug; 45(6):455-61. PubMed ID: 25014623
    [Abstract] [Full Text] [Related]

  • 22. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
    Kendrick JE, Straughn JM, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD, Buchsbaum DJ.
    Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
    [Abstract] [Full Text] [Related]

  • 23. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM, van der Zee AG, van den Heuvel FA, Timmer T, de Vries EG, de Jong S.
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [Abstract] [Full Text] [Related]

  • 24. Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds.
    Joanitti GA, Azevedo RB, Freitas SM.
    Cancer Lett; 2010 Jul 01; 293(1):73-81. PubMed ID: 20133052
    [Abstract] [Full Text] [Related]

  • 25. Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
    Yokoyama M, Noguchi M, Nakao Y, Ysunaga M, Yamasaki F, Iwasaka T.
    Gynecol Oncol; 2008 Feb 01; 108(2):326-31. PubMed ID: 18035403
    [Abstract] [Full Text] [Related]

  • 26. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
    Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakóbisiak M, Golab J.
    Int J Oncol; 2004 May 01; 24(5):1149-57. PubMed ID: 15067336
    [Abstract] [Full Text] [Related]

  • 27. The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA repair via epidermal growth factor receptor phosphorylation and nuclear transport.
    Dittmann K, Mayer C, Kehlbach R, Rodemann HP.
    Radiother Oncol; 2008 Mar 01; 86(3):375-82. PubMed ID: 18237807
    [Abstract] [Full Text] [Related]

  • 28. Complete amino acid sequence of the lentil trypsin-chymotrypsin inhibitor LCI-1.7 and a discussion of atypical binding sites of Bowman-Birk inhibitors.
    Weder JK, Hinkers SC.
    J Agric Food Chem; 2004 Jun 30; 52(13):4219-26. PubMed ID: 15212472
    [Abstract] [Full Text] [Related]

  • 29. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX, Kakehi Y.
    Clin Cancer Res; 2009 Mar 15; 15(6):2039-47. PubMed ID: 19276256
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis.
    Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D.
    Mol Carcinog; 2005 Sep 15; 44(1):51-9. PubMed ID: 16044419
    [Abstract] [Full Text] [Related]

  • 33. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia.
    Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL.
    Cancer Epidemiol Biomarkers Prev; 2000 Jan 15; 9(1):43-7. PubMed ID: 10667462
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L, Davis R, Anwar A, Behbakht K.
    Gynecol Oncol; 2008 Sep 15; 110(3):425-31. PubMed ID: 18619662
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V, Blanárová O, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Fedorocko P, Kozubík A.
    Gynecol Oncol; 2006 Jul 15; 102(1):32-40. PubMed ID: 16364413
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.